The stock of Atossa Therapeutics Inc (NASDAQ:ATOS) last traded at $0.88, up 0.24% from the previous session.
ATOS stock price is now 5.59% away from the 50-day moving average and -13.08% away from the 200-day moving average. The market capitalization of the company currently stands at $113.61M.
With the price target of $2, Maxim Group recently initiated with Buy rating for Atossa Therapeutics Inc (NASDAQ: ATOS).
In other news, QUAY STEVEN C, President & CEO bought 11,239 shares of the company’s stock on May 21 ’25. The stock was bought for $9,887 at an average price of $0.88. Upon completion of the transaction, the President & CEO now directly owns 13,898 shares in the company, valued at $12230.24. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 26 ’25, Director Remmel H. Lawrence bought 10,000 shares of the business’s stock. A total of $7,000 was incurred on buying the stock at an average price of $0.70. This leaves the insider owning 10,257 shares of the company worth $9026.16. A total of 0.04% of the company’s stock is owned by insiders.
During the past 12 months, Atossa Therapeutics Inc has had a low of $0.55 and a high of $1.66. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 12.67, and a quick ratio of 12.67. The fifty day moving average price for ATOS is $0.8332 and a two-hundred day moving average price translates $1.0119 for the stock.
The latest earnings results from Atossa Therapeutics Inc (NASDAQ: ATOS) was released for 2025-03-31.
